Ustekinumab - Latest Advances

Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.

Journal: Expert opinion on biological therapy

Published: October 16, 2025

Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Journal: Cureus

Published: September 26, 2025

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 25, 2025

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study.

Journal: Expert opinion on pharmacotherapy

Published: September 18, 2025

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.

Journal: Journal of Crohn's & colitis

Published: September 08, 2025

Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management.

Journal: Expert opinion on biological therapy

Published: September 05, 2025

Perspective: Making Treatment Decisions for Crohn's Disease in 2025-Key Considerations.

Journal: Journal of clinical medicine

Published: September 04, 2025

Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.

Journal: Journal of Crohn's & colitis

Published: September 03, 2025

Long-term effectiveness and safety of ustekinumab in patients with Crohn's disease: real-world evidence.

Journal: Expert opinion on biological therapy

Published: September 02, 2025

Comparative Effectiveness of Risankizumab Versus Ustekinumab in Bio-naive CD Patients: A Real-World Multicenter Retrospective Cohort Study.

Journal: Gastroenterology & hepatology

Published: September 02, 2025

Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.

Journal: Gastroenterology & hepatology

Published: September 02, 2025

Comment on "A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease".

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: August 20, 2025

Filters

Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.

Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.

Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study.

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study.

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.

Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management.

Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management.

Perspective: Making Treatment Decisions for Crohn's Disease in 2025-Key Considerations.

Perspective: Making Treatment Decisions for Crohn's Disease in 2025-Key Considerations.

Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.

Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.

Long-term effectiveness and safety of ustekinumab in patients with Crohn's disease: real-world evidence.

Long-term effectiveness and safety of ustekinumab in patients with Crohn's disease: real-world evidence.

Comparative Effectiveness of Risankizumab Versus Ustekinumab in Bio-naive CD Patients: A Real-World Multicenter Retrospective Cohort Study.

Comparative Effectiveness of Risankizumab Versus Ustekinumab in Bio-naive CD Patients: A Real-World Multicenter Retrospective Cohort Study.

Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.

Low Remission Recapture After Ustekinumab Dose Optimization in CD: Results of the Randomized Placebo-Controlled Double-Blind REScUE Study.

Comment on "A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease".

Comment on "A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease".